Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space.

"CONFLICT OF INTEREST STATEMENT Tejal Desai is a scientific founder of Encellin, a cell therapy device company, and she is listed as an inventor of a thin film macro‐encapsulation technology (US Patent no. 10,865,378). Julie B. Sneddon has served on the Scientific Advisory Board (SAB) of Encellin Inc. No direct funds have been given to Julie B. Sneddon or her lab by Encellin Inc. Qizhi Tang is a SAB member and holds stocks in Encellin Inc and Minutia Inc. Matthias Hebrok holds stocks in Encellin Inc, Thymmune Therapeutics Inc, and has received research support from Eli Lilly. He is the co‐founder and SAB member of Minutia Inc. and holds stocks and options in the company."

"Gauree Chendke, Bhushan Kharbikar, Gaetano Faleo, Qizhi Tang, and Tejal Desai designed experiments. Gauree Chendke wrote the article, fabricated encapsulation devices, helped with in vivo experiments, performed histology, and obtained and analyzed all images. Bhushan Kharbikar performed the in vivo device implantation, bioluminescent imaging, and IPGTT. Sudipta Ashe performed differentiation of stem cell‐derived insulin‐producing beta cell clusters and performed and analyzed the ELISA data. Julie B. Sneddon, Qizhi Tang, Matthias Hebrok, and Tejal Desai provided direction, supervised the project, and edited the article. This work was supported by NIH T32 UCSF ipCSB 2T32EB009383‐11A1, NIH T32 UC Berkeley – UCSF joint program in Bioengineering T32GM139794, UCSF Discovery Fellowship and Achievement Rewards for College Scientists (ARCS) Fellowship (to Gauree Chendke), Diabetes Research Connection grant A135548 (to Bhushan Kharbikar), and JDRF grants 2‐SRA‐2022‐1221‐S‐B, 3‐SRA‐2022‐1216‐S‐B (to Tejal Desai), and 2‐SRA‐2022‐1256‐S‐B (to Julie B. Sneddon)."